Nigella sativa in vitro/in vivo Lieshmanial in vitro ex vivo in vitro anti-Lieshmanial In vivo anti-Lieshmanial n In vitro anti-Lieshmanial p in vivo anti-Lieshmanial
View Article and Find Full Text PDFMetastatic malignant melanoma remains a highly aggressive form of skin cancer for which no reliable methods for treatment exist. Given the increasing incidence of this cancer, considerable attention has focused on the development of new and improved methods for tackling this disease. Within this article, methods for treating melanoma are reviewed and discussed with particular attention focusing on prodrugs that are activated by the tyrosinase enzyme.
View Article and Find Full Text PDFThe suitability of 4-di(2-chloroethyl)aminoanilino-4-hydroxyphenethylaminomethanone 2 to act as a prodrug for melanocyte-directed enzyme prodrug therapy (MDEPT) is assessed. Thus its synthesis, ability to generate a cytotoxic agent upon exposure to tyrosinase, and stability within different sera are reported. A comparison is made to illustrate that the new urea prodrug 2 is a more suitable candidate for MDEPT than the corresponding carbamate prodrug 1.
View Article and Find Full Text PDF